S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.36%) $91.45

实时更新: Inventiva SA [IVA.PA]

交易所: EURONEXT 工业: Biotechnology
最后更新时间3 May 2024 @ 23:35

5.69% 3.16

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:35):

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases...

Stats
今日成交量 37 188.00
平均成交量 66 924.00
市值 165.49M
EPS €0 ( 2024-03-28 )
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -1.300
ATR14 €0.0110 (0.35%)

音量 相关性

長: -0.05 (neutral)
短: -0.36 (neutral)
Signal:(48.529) Neutral

Inventiva SA 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Inventiva SA 相关性 - 货币/商品

The country flag -0.60
( weak negative )
The country flag -0.81
( strong negative )
The country flag 0.00
( neutral )
The country flag -0.78
( moderate negative )
The country flag 0.68
( moderate )
The country flag 0.63
( weak )

Inventiva SA 财务报表

Annual 2023
营收: €17.48M
毛利润: €17.50M (100.13 %)
EPS: €-2.43
FY 2023
营收: €17.48M
毛利润: €17.50M (100.13 %)
EPS: €-2.43
FY 2022
营收: €12.18M
毛利润: €11.18M (91.83 %)
EPS: €-1.310
FY 2021
营收: €4.19M
毛利润: €0.00 (0.00 %)
EPS: €-1.465

Financial Reports:

No articles found.

Inventiva SA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。